nimotuzumab
mAbexperimental
Nimotuzumab is a humanized monoclonal antibody that as of 2014 had orphan status in the US and EU for glioma, and marketing approval in India, China, and other countries for squamous cell carcinomas of the head and neck, and was undergoing several clinical trials. — Wikipedia
Clinical trial activity
136 trials · 105 clinical orgs · 0 marketing orgs
Phase 1
17
Phase 2
116
Phase 3
27
Phase 4
3
Earliest trial started Jan 1, 2002 (NCT04821843)
Timeline
Indications
Approved for
Studied for
- Adenocarcinoma · Phase 2/Phase 3
- Antibody-Dependent Cell Cytotoxicity · Phase 1
- Brain Neoplasms · Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma · Phase 3
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Squamous Cell · Phase 2
- Carcinoma, Transitional Cell · Phase 1
- Chemoradiotherapy · Phase 3
- Colorectal Neoplasms · Phase 3
- Diffuse Intrinsic Pontine Glioma · Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 3
- Drugs, Investigational · Phase 2
- Drug Therapy · Phase 2
- Electroconvulsive Therapy · Phase 2
- ErbB Receptors · Phase 2
- Esophageal Diseases · Phase 2
- Esophageal Neoplasms · Phase 3
- Esophageal Squamous Cell Carcinoma · Phase 2/Phase 3
- General Surgery · Phase 3
- Glioblastoma · Phase 3
- Glioma · Phase 2
- Head and Neck Neoplasms · Phase 4
- Hypopharyngeal Neoplasms · Phase 2
- Immunotherapy · Phase 3
- Lung Neoplasms · Phase 2
- Mutation · Phase 1/Phase 2
- Nasopharyngeal Carcinoma · Phase 4
- Nasopharyngeal Diseases · Phase 3
- Nasopharyngeal Neoplasms · Phase 3
- Natural Killer T-Cells · Phase 1
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 2
- Neuroendocrine Tumors · Phase 2
- Oropharyngeal Neoplasms · Phase 2
- Palliative Care · Phase 3
- Pancreatic Neoplasms · Phase 4
- Penile Neoplasms · Phase 2
- Progression-Free Survival · Phase 2
- Prosthesis Failure · Phase 3
- Radiation Oncology · Phase 2
- Radiotherapy · Phase 2
- Rectal Neoplasms · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 3
- Stomach Neoplasms · Phase 3
- Uterine Cervical Neoplasms · Phase 3
- Uterine Neoplasms · Phase 2
Mechanism of action
EGFR inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaNimotuzumab ↗
- ChEMBLCHEMBL2108359 ↗
Also known as
- hr3
- immunoglobulin g1, anti-(humanized mouse monoclonal hr3 beta1 chain anti-human epidermal growth factor receptor), disulfide with humanized mouse monoclonal hr3 kappa-chain, dimer
- nimotuzumab
- nimotuzumab
- nimotuzumab
- theracim-hr3
- theraloc
- theraloc
- theraloc theracim
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07310771 | Phase 2 | Jan 10, 2026 | Fujian Medical University |
| NCT07277452 | Phase 2 | Dec 10, 2025 | Nanjing Medical University, Peking University |
| NCT07240766 | Phase 2 | Nov 15, 2025 | Zhejiang University |
| NCT07312578 | Phase 2 | Nov 1, 2025 | Peking University |
| NCT07053735 | Phase 1 | Jun 30, 2025 | Peking University |
| NCT07070479 | Phase 2 | Jun 24, 2025 | Sun Yat-Sen University |
| NCT06912711 | Phase 2 | May 16, 2025 | Sun Yat-Sen University |
| NCT07105592 | Phase 1/Phase 2 (Phase 2) | May 13, 2025 | Fudan University |
| NCT06938503 | Phase 2 | Apr 21, 2025 | Tianjin Medical University |
| NCT06770452 | Phase 2 | Feb 1, 2025 | Zhejiang University |
| NCT06773130 | Phase 1/Phase 2 (Phase 2) | Jan 31, 2025 | Sichuan University |
| NCT06781086 | Phase 2 | Jan 20, 2025 | Biotech Pharmaceutical Co., Ltd., Nanjing Medical University, Peking University |
| NCT06722911 | Phase 2 | Nov 15, 2024 | Zhejiang University |
| NCT06676722 | Phase 2 | Nov 5, 2024 | Xiamen University |
| NCT06509009 | Phase 2 | Aug 30, 2024 | Chinese Academy of Medical Sciences |
| NCT06561763 | Phase 3 | Aug 20, 2024 | Sun Yat-Sen University |
| NCT06490341 | Phase 2 | Jul 20, 2024 | Chinese Academy of Medical Sciences |
| NCT06429904 | Phase 2 | May 15, 2024 | Chinese Academy of Medical Sciences |
| NCT06409429 | Phase 2/Phase 3 (Phase 3) | May 1, 2024 | Tianjin Medical University |
| NCT06343116 | Phase 3 | Apr 30, 2024 | Biotech Pharmaceutical Co., Ltd., Peking University |
Showing 20 of 136 trials
Page 1 / 7
Organizations
Research & Development (105)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biotech Pharmaceutical Co., Ltd. | For profit | 27 | 21 | 5 | 2008 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 25 | 18 | 5 | 2002 |
| Peking University | Academic/Hospital | 18 | 10 | 4 | 2009 |
| Sun Yat-Sen University | Academic/Hospital | 15 | 11 | 2 | 2009 |
| Fudan University | Academic/Hospital | 10 | 8 | 3 | 2009 |
| Zhejiang University | Academic/Hospital | 10 | 9 | 1 | 2012 |
| Tianjin Medical University | Academic/Hospital | 8 | 6 | 3 | 2011 |
| Jiao Tong University | Academic/Hospital | 7 | 3 | 2 | 2009 |
| Fujian Medical University | Academic/Hospital | 6 | 2 | 2 | 2012 |
| Nanjing Medical University | Academic/Hospital | 6 | 4 | 3 | 2011 |
| YM Biosciences | For profit | 6 | 5 | 2 | 2005 |
| People's Liberation Army of China | Government | 5 | 2 | 3 | 2015 |
| Eurofarma Laboratorios S.A. | For profit | 4 | 4 | 2 | 2009 |
| University of Toronto | Academic/Hospital | 4 | 0 | 2 | 2005 |
| Guangxi Medical University | Academic/Hospital | 3 | 1 | 3 | 2012 |
| Guangzhou Medical University | Academic/Hospital | 3 | 0 | 3 | 2012 |
| Hebei University | Academic/Hospital | 3 | 0 | 2 | 2016 |
| Jiangxi Provincial Cancer Hospital | Academic/Hospital | 3 | 1 | 1 | 2012 |
| Xiamen University | Academic/Hospital | 3 | 1 | 2 | 2012 |
| Central South University | Academic/Hospital | 2 | 0 | 2 | 2012 |
105 organizations
Page 1 / 6